Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Actavis announced that it will continue to distribute Namenda (memantine HCI) tablets due to a recent decision by a panel of the U.S. Court of Appeals for the Second Circuit.
The Court ruled to uphold a December 15, 2014 preliminary injunction requiring Actavis to continue distribution of Namenda 5mg and 10mg tablets. Forest Laboratories, a wholly owned subsidiary of Actavis, had previously announced plans to discontinue sales of the drug in the fall of 2014.
RELATED: Alzheimer’s Disease Drug to be Discontinued
Namenda is an NMDA receptor antagonist approved for the treatment of moderate-to-severe dementia of the Alzheimer’s type. It is also available as Namenda oral solution and Namenda XR extended-release capsules.
For more information call (844) 873-2823 or visit Namenda.com.
